Alnylam Pharmace. buy JPMorgan Chase & Co.
Summary
This prediction ended on 17.07.26 with a price of €245.00. The price of Alnylam Pharmace. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.71%. JPMorgan_Chase___Co_ has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. JPMorgan_Chase___Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -1.828% | -1.828% | -50.133% |
| iShares Core DAX® | 1.001% | 4.831% | 8.149% |
| iShares Nasdaq 100 | 2.702% | -1.720% | 26.924% |
| iShares Nikkei 225® | 3.519% | -3.506% | 48.064% |
| iShares S&P 500 | 1.766% | 1.273% | 23.577% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.
Current prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace.
Alnylam Pharmace.
13.10.25
13.10.26
11.08.26
Stopped prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace.
Alnylam Pharmace.
31.07.26
31.07.27
11.08.26
Alnylam Pharmace.
22.07.26
22.07.27
11.08.26
Alnylam Pharmace.
12.06.25
12.06.26
13.06.26
Alnylam Pharmace.
24.03.25
24.03.26
25.03.26

